Compare Cardinal Health Inc (CAH) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Nasdaq Inc — how do they compare? Cardinal Health Inc trades at $229.55 (market cap $53.89B), while Nasdaq Inc trades at $90.88 (market cap $49.77B). The key difference: Cardinal Health Inc and Nasdaq Inc are close in size by market cap, and Nasdaq Inc pays the higher dividend (1.27%). Which is the better fit depends on your goals.
| CAH | NDAQ | |
|---|---|---|
Market Cap | $53.89B | $49.77B |
Sector | Health | Financials |
52-Week High | $239.71 | $100.98 |
52-Week Low | $146.04 | $76.85 |
Enterprise Value | $58.87B | $56.84B |
Dividend Yield | 0.89% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Nasdaq (NDAQ) trades at $89.21, up 1.28% with a bullish technical signal and strong earnings momentum, beating estimates for three consecutive quarters. The company reported robust 2025 revenue of $8.26 billion and net income of $1.79 billion, with a net margin of 23.03%. Recent news highlights include SK Hynix's Nasdaq debut and positive analyst coverage, with 61% of analysts rating it a buy.
Outlook remains positive given earnings consistency and a $105.60 consensus price target, but risks include high valuation multiples and debt levels. Cash flow volatility from investing and financing activities warrants monitoring, though operational strength supports growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
